Opportunistic Infections Are More Prevalent in Crohn's Disease and Ulcerative Colitis: A Large Population-Based Study.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
06 01 2020
Historique:
pubmed: 18 7 2019
medline: 24 10 2020
entrez: 18 7 2019
Statut: ppublish

Résumé

Opportunistic infections (OIs) are more common in patients with inflammatory bowel disease (IBD); however, there have been limited large-scale studies of OIs in IBD. We investigated the epidemiological characteristics of OI in Crohn's disease (CD) and ulcerative colitis (UC) using a large population-based database. Data were collected from a commercial database (Explorys Inc., Cleveland, OH, USA) that provided electronic health records from 26 major integrated US health care systems from 1999 to March 2018. In this data set, we identified all CD and UC patients, based on Systemized Nomenclature of Medicine-Clinical Terms. Within these cohorts, we identified a variety of OIs and compared the prevalence rate of OI in individuals with IBD with that of controls (patients in the database between March 2013 and March 2018 without the diagnosis of IBD). Explorys included 153,290 patients with CD and 128,540 patients with UC between March 2013 and March 2018. The prevalence of OIs was 17.8% in CD, 19.2% in UC, and 7% in non-IBD controls. When compared with non-IBD controls, all OIs were more common in CD (prevalence ratio [PR], 2.54; 95% confidence interval [CI], 2.51-2.57) and UC (PR, 2.74; 95% CI, 2.71-2.77). Overall, viral infections were numerically more common, whereas bacterial infections had the highest PRs in CD and UC when compared with controls without IBD. We found significantly higher rates of OI in IBD. Our study suggests the need for close follow-up of IBD patients to diagnose and provide vaccinations where applicable for prevention of infections.

Sections du résumé

BACKGROUND
Opportunistic infections (OIs) are more common in patients with inflammatory bowel disease (IBD); however, there have been limited large-scale studies of OIs in IBD. We investigated the epidemiological characteristics of OI in Crohn's disease (CD) and ulcerative colitis (UC) using a large population-based database.
METHODS
Data were collected from a commercial database (Explorys Inc., Cleveland, OH, USA) that provided electronic health records from 26 major integrated US health care systems from 1999 to March 2018. In this data set, we identified all CD and UC patients, based on Systemized Nomenclature of Medicine-Clinical Terms. Within these cohorts, we identified a variety of OIs and compared the prevalence rate of OI in individuals with IBD with that of controls (patients in the database between March 2013 and March 2018 without the diagnosis of IBD).
RESULTS
Explorys included 153,290 patients with CD and 128,540 patients with UC between March 2013 and March 2018. The prevalence of OIs was 17.8% in CD, 19.2% in UC, and 7% in non-IBD controls. When compared with non-IBD controls, all OIs were more common in CD (prevalence ratio [PR], 2.54; 95% confidence interval [CI], 2.51-2.57) and UC (PR, 2.74; 95% CI, 2.71-2.77). Overall, viral infections were numerically more common, whereas bacterial infections had the highest PRs in CD and UC when compared with controls without IBD.
CONCLUSIONS
We found significantly higher rates of OI in IBD. Our study suggests the need for close follow-up of IBD patients to diagnose and provide vaccinations where applicable for prevention of infections.

Identifiants

pubmed: 31314891
pii: 5533446
doi: 10.1093/ibd/izz147
pmc: PMC7327158
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

291-300

Subventions

Organisme : NIDDK NIH HHS
ID : K08 DK110421
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Inflamm Bowel Dis. 2011 Sep;17(9):2023-4
pubmed: 21287669
JAMA Dermatol. 2018 Jul 1;154(7):814-818
pubmed: 29800049
Emerg Infect Dis. 2016 Mar;22(3):370-8
pubmed: 26890817
Clin Gastroenterol Hepatol. 2017 Nov;15(11):1733-1741
pubmed: 28603057
J Crohns Colitis. 2013 Feb;7(1):e11-4
pubmed: 22647638
Mult Scler Relat Disord. 2019 Feb;28:69-74
pubmed: 30557818
Inflamm Bowel Dis. 2013 Jul;19(8):1710-6
pubmed: 23574759
J Crohns Colitis. 2016 Sep;10(9):1127-8
pubmed: 26944414
Gastroenterology. 2015 May;148(5):e12-3
pubmed: 25824348
Clin Gastroenterol Hepatol. 2015 Jan;13(1):131-7; quiz e7
pubmed: 24993369
Clin Gastroenterol Hepatol. 2017 Jun;15(6):857-863
pubmed: 27856364
Mycoses. 2018 Jun;61(6):366-376
pubmed: 29453860
J Am Med Inform Assoc. 2010 Sep-Oct;17(5):602-7
pubmed: 20819871
Dig Dis Sci. 2013 Feb;58(2):519-25
pubmed: 22926499
Dig Dis Sci. 2018 Jul;63(7):1929-1936
pubmed: 29675660
Am J Gastroenterol. 2015 Nov;110(11):1582-7
pubmed: 26346865
Inflamm Bowel Dis. 2019 Jan 10;25(2):369-376
pubmed: 30020478
Eur J Gastroenterol Hepatol. 2014 Nov;26(11):1247-52
pubmed: 25171025
Inflamm Bowel Dis. 2009 Aug;15(8):1240-4
pubmed: 19217020
J Am Med Inform Assoc. 2012 Nov-Dec;19(6):965-72
pubmed: 22759621
Am J Gastroenterol. 2017 Feb;112(2):241-258
pubmed: 28071656
Aliment Pharmacol Ther. 2009 May 15;29(10):1106-13
pubmed: 19222411
Am J Gastroenterol. 2010 Mar;105(3):501-23; quiz 524
pubmed: 20068560
J Crohns Colitis. 2014 Jun;8(6):443-68
pubmed: 24613021
Inflamm Bowel Dis. 2019 May 4;25(6):1080-1087
pubmed: 30500938
J Neurol Sci. 2006 Sep 25;247(2):236-8
pubmed: 16815466
Gastroenterol Clin North Am. 2014 Sep;43(3):405-24
pubmed: 25110250
Inflamm Bowel Dis. 2014 Jan;20(1):196-212
pubmed: 24051931
Inflamm Bowel Dis. 2012 Jun;18(6):1057-63
pubmed: 21953829
World J Gastroenterol. 2015 Jun 7;21(21):6491-8
pubmed: 26074688
Gastroenterology. 2017 Aug;153(2):430-438.e2
pubmed: 28479377
Emerg Infect Dis. 2011 Sep;17(9):1664-9
pubmed: 21888792
Am J Gastroenterol. 2013 Feb;108(2):240-8
pubmed: 23295276
J Pediatr Gastroenterol Nutr. 2013 Oct;57(4):487-8
pubmed: 23783013
Am J Gastroenterol. 2018 Apr;113(4):481-517
pubmed: 29610508

Auteurs

Mohammed Zaahid Sheriff (MZ)

Department of Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.

Emad Mansoor (E)

Division of Gastroenterology and Liver Disease, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.

Jay Luther (J)

Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

Ashwin N Ananthakrishnan (AN)

Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

Mohannad Abou Saleh (M)

Department of Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.

Edith Ho (E)

Division of Gastroenterology and Liver Disease, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.

Farren B S Briggs (FBS)

Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

Maneesh Dave (M)

Division of Gastroenterology and Liver Disease, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH